West Pharmaceutical Services
Market Cap
US$10.6b
Last Updated
2019/09/15 23:45 UTC
Data Sources
Company Financials +
Executive Summary
West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally.
Snowflake
Fundamentals
Flawless balance sheet with solid track record.
Similar Companies
Share Price & News
How has West Pharmaceutical Services's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-3.7%
NYSE:WST
-0.9%
US Medical Equipment
1.3%
US Market
1 Year Return
19.6%
NYSE:WST
9.1%
US Medical Equipment
2.0%
US Market
WST outperformed the Medical Equipment industry which returned 8.7% over the past year.
WST outperformed the Market in United States of America which returned 1.7% over the past year.
Share holder returns
| WST | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.7% | -0.9% | 1.3% |
| 30 Day | -0.6% | 0.7% | 3.9% |
| 90 Day | 19.5% | 4.4% | 3.4% |
| 1 Year | 20.2%19.6% | 10.0%9.1% | 4.2%2.0% |
| 3 Year | 80.3%77.2% | 70.7%65.5% | 47.2%37.6% |
| 5 Year | 232.9%221.9% | 130.7%104.3% | 60.5%42.9% |
Price Volatility Vs. Market
How volatile is West Pharmaceutical Services's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Does West Pharmaceutical Services (NYSE:WST) Deserve A Spot On Your Watchlist?3 weeks ago | Simply Wall St
What Do Analysts Think About West Pharmaceutical Services, Inc.'s (NYSE:WST) Growth?1 month ago | Simply Wall St
Why You Should Buy West Pharmaceutical Services, Inc. (NYSE:WST) In This Bear MarketValuation
Is West Pharmaceutical Services undervalued based on future cash flows and its price relative to the stock market?
46.63x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
West Pharmaceutical Services's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
West Pharmaceutical Services's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
West Pharmaceutical Services is overvalued based on earnings compared to the US Medical Equipment industry average.
West Pharmaceutical Services is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
West Pharmaceutical Services is poor value based on expected growth next year.
Price Based on Value of Assets
West Pharmaceutical Services is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is West Pharmaceutical Services expected to perform in the next 1 to 3 years based on estimates from 6 analysts?
10.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
West Pharmaceutical Services's revenue is expected to grow by 6.5% yearly, however this is not considered high growth (20% yearly).
West Pharmaceutical Services's earnings are expected to grow by 10% yearly, however this is not considered high growth (20% yearly).
West Pharmaceutical Services's revenue growth is positive but not above the United States of America market average.
West Pharmaceutical Services's earnings growth is positive but not above the United States of America market average.
West Pharmaceutical Services's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
West Pharmaceutical Services is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has West Pharmaceutical Services performed over the past 5 years?
13.9%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
West Pharmaceutical Services's year on year earnings growth rate has been positive over the past 5 years.
West Pharmaceutical Services's 1-year earnings growth exceeds its 5-year average (51.8% vs 13.9%)
West Pharmaceutical Services's earnings growth has exceeded the US Medical Equipment industry average in the past year (51.8% vs 28.9%).
Return on Equity
West Pharmaceutical Services has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
West Pharmaceutical Services used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
Return on Capital Employed
West Pharmaceutical Services has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is West Pharmaceutical Services's financial position?
Financial Position Analysis
West Pharmaceutical Services is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
West Pharmaceutical Services's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
West Pharmaceutical Services's level of debt (13.6%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (37.6% vs 13.6% today).
Debt is well covered by operating cash flow (160.4%, greater than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 46.5x coverage).
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 4.8x debt.
Next Steps
Dividend
What is West Pharmaceutical Services's current dividend yield, its reliability and sustainability?
0.45%
Expected Dividend Yield
Upcoming Dividend Payment
Purchase West Pharmaceutical Services before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield and Payments Analysis
West Pharmaceutical Services's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.45%).
West Pharmaceutical Services's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).
West Pharmaceutical Services is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
West Pharmaceutical Services is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to Shareholders
No need to calculate the sustainability of West Pharmaceutical Services's dividends as it is not paying a notable one for United States of America.
Future Payout to Shareholders
No need to calculate the sustainability of West Pharmaceutical Services's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of West Pharmaceutical Services's salary, the management and board of directors tenure and is there insider trading?
3.7yrs
Average management tenure
CEO
Eric Green (49yo)
4.4yrs
Tenure
US$4,756,563
Compensation
Mr. Eric M. Green has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its President since December 17, 2015. Mr. Green served as Executive Vice President and ...
CEO Compensation Analysis
Insufficient data for Eric to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Eric's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
3.7yrs
Average Tenure
54.5yo
Average Age
The tenure for the West Pharmaceutical Services management team is about average.
Board Age and Tenure
6.6yrs
Average Tenure
58.5yo
Average Age
The tenure for the West Pharmaceutical Services board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
David Montecalvo (54yo)
Senior VP and Chief Operations & Supply Chain Officer
- Tenure: 3yrs
- Compensation: US$1.11m
Richard Luzzi (67yo)
Senior Vice President of Human Resources
- Tenure: 17.3yrs
Eric Green (49yo)
CEO, President & Director
- Tenure: 4.4yrs
- Compensation: US$4.76m
Quintin Lai
Vice President of Corporate Development
- Tenure: 3.7yrs
George Miller (64yo)
Senior VP
- Tenure: 3.8yrs
- Compensation: US$1.37m
Eric Resnick (55yo)
CTO & VP
- Tenure: 3.5yrs
Karen Flynn (56yo)
Chief Commercial Officer & Senior VP
- Tenure: 3.7yrs
- Compensation: US$1.90m
Annette Favorite (54yo)
Chief Human Resources Officer & Senior VP
- Tenure: 3.9yrs
- Compensation: US$1.14m
Bernard Birkett (50yo)
Senior VP
- Tenure: 1.3yrs
Emily Denney
Vice President of Global Communications
- Tenure: 0yrs
Board Members
Myla Lai-Goldman (61yo)
Director
- Tenure: 5.6yrs
- Compensation: US$243.61k
Thomas Hofmann (67yo)
Director
- Tenure: 11.9yrs
- Compensation: US$257.92k
Pat Zenner (72yo)
Chairman of the Board
- Tenure: 4.2yrs
- Compensation: US$368.43k
Mark Buthman (58yo)
Director
- Tenure: 8.6yrs
- Compensation: US$273.85k
Doug Michels (62yo)
Director
- Tenure: 8.6yrs
- Compensation: US$291.05k
Paula Johnson (59yo)
Director
- Tenure: 13.9yrs
- Compensation: US$271.35k
Paolo Pucci (58yo)
Director
- Tenure: 3yrs
- Compensation: US$241.62k
Eric Green (49yo)
CEO, President & Director
- Tenure: 4.4yrs
- Compensation: US$4.76m
Bill Feehery (48yo)
Director
- Tenure: 7.6yrs
- Compensation: US$258.50k
Deb Keller (56yo)
Independent Director
- Tenure: 2.3yrs
- Compensation: US$193.87k
Company Information
West Pharmaceutical Services, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: West Pharmaceutical Services, Inc.
- Ticker: WST
- Exchange: NYSE
- Founded: 1923
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$10.635b
- Shares outstanding: 73.75m
- Website: https://www.westpharma.com
Number of Employees
Location
- West Pharmaceutical Services, Inc.
- 530 Herman O. West Drive
- Exton
- Pennsylvania
- 19341
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| WST | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Dec 1972 |
| WPS | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Dec 1972 |
Biography
West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, Sout ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/15 23:45 |
| End of Day Share Price | 2019/09/13 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.